Reuters logo
BRIEF-New analysis shows Repatha reduces risk of cardiovascular events
August 29, 2017 / 8:10 PM / a month ago

BRIEF-New analysis shows Repatha reduces risk of cardiovascular events

Aug 30 (Reuters) - Amgen Inc

* New analysis shows repatha® (evolocumab) reduces cardiovascular events in patients with history of stroke

* Amgen says ‍no new safety concerns were identified in the cohort of more than 5,000 patients​

* ‍Amgen - Study also found a statistically significant 15 percent reduction in risk of extended mace composite (primary) endpoint ​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below